Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lexaria Bioscience ( (LEXX) ) has shared an announcement.
Lexaria Bioscience has reached a significant milestone by securing its 50th patent, with new patents granted in Australia for epilepsy treatment and in Japan for sublingual nicotine delivery. This expansion of its patent portfolio is expected to enhance Lexaria’s potential for commercial deals in the pharmaceutical industry and strengthen its long-term value for shareholders. The epilepsy and nicotine markets, both of which are projected to grow substantially in the coming years, present significant opportunities for Lexaria’s DehydraTECH technology, which has demonstrated improved absorption benefits.
The most recent analyst rating on (LEXX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, known for its patented DehydraTECH technology, which enhances the bio-absorption of active pharmaceutical ingredients through oral delivery. The company operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted worldwide.
Average Trading Volume: 102,778
Technical Sentiment Signal: Sell
Current Market Cap: $18.7M
For an in-depth examination of LEXX stock, go to TipRanks’ Overview page.